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Abstract
Background: Bangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the
World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease
and affect the attempts to curb transmission of drug resistant tuberculosis. The main objective of this study was to
investigate the health system delay in multidrug resistant tuberculosis treatment in Bangladesh and to explore the
factors related to the delay.
Methods: Information related to the delay was collected as part of a previously conducted case–control study.
The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using
rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). Information was collected by face-to-face
interviews and through record reviews from all three Government hospitals providing multidrug resistant tuberculosis
services, from September 2012 to April 2013. Multivariable regression analysis was performed using Bootstrap variance
estimators. Definitions were as follows: Provider delay: time between visiting a provider for first consultation on MDR-TB
related symptom to visiting a designated diagnostic centre for testing; Diagnostic delay: time from date of diagnostic
sample provided to date of result; Treatment initiation delay: time between the date of diagnosis and date of
treatment initiation; Health system delay: time between visiting a provider to start of treatment. Health system
delay was derived by adding provider delay, diagnostic delay and treatment initiation delay.
Results: The 207 multidrug resistant tuberculosis patients experienced a health system delay of median 7.1 weeks. The
health system delay consists of provider delay (median 4 weeks), diagnostic delay (median 5 days) and treatment
initiation delay (median 10 days). Health system delay (Coefficient: 37.7; 95 %; CI 15.0–60.4; p 0.003) was associated with
the visit to private practitioners for first consultation.
Conclusions: Diagnosis time for multidrug resistant tuberculosis was fast using the rapid tests. However, some degree
of delay was present in treatment initiation, after diagnosis. The most effective way to reduce health system delay
would be through strategies such as engaging private practitioners in multidrug resistant tuberculosis control.
Keywords: Delay, MDR-TB, Multidrug resistant tuberculosis, Barrier to treatment, Health system, Private
practitioner
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Background
Multidrug resistant tuberculosis (MDR-TB) is a major
challenge to worldwide tuberculosis (TB) control [1].
Despite the progress in detection, in 2013 a total of 55 %
the estimated MDR-TB were under-detected and 29 %
of the diagnosed patients were not on treatment [2].
Delay in TB treatment may result in disease transmis-
sion, progression, and poor treatment outcome including
increased risk of death [3]. Several studies have reported
that delay in TB initiating treatment contributed to de-
velopment of MDR-TB [4–6].
Bangladesh is one of the high burden countries for TB
and has also been listed on the 27 high burden countries
for MDR-TB by the World Health Organization (WHO)
[2]. Due to the overall high TB burden in Bangladesh,
the proportion of patients with MDR-TB (1.4 % and
29 %, among the new and previously treated TB patients,
respectively) amounts to 4700 people (2100 and 2600
among new and previously treated TB patients, respect-
ively), which provides a significant challenge for the na-
tional tuberculosis control programme [2].
Delay in MDR-TB treatment may cause more suffering
to the affected patients as well as hinder the attempts to
curb the spread of MDR-TB. Delay in initiation of tuber-
culosis treatment among the drug sensitive TB patients
has been reported in many studies [7]. Some studies
reported delay in commencing treatment of MDR-TB
patients, although diagnostic and treatment initiation
delays were frequently reported in these studies; the
context and definition of delays were variable [8–14].
Some studies focused on rapid diagnostic methods for
MDR-TB detection, reporting either the time taken for
diagnosis or time from diagnosis to treatment initiation
[8, 10, 14, 15]. We could only find one study on
patient-related delay among the MDR-TB patients and
its associated factors, a qualitative study carried out in
Cape Town, South Africa [16]. The study reported in-
accurate perception of their symptoms as an important
factor in the delay in seeking care. Diagnostic delay was
inherent in the MDR-TB management procedure while
the diagnosis of MDR-TB relied on culture methods,
which require longer time than the more advanced tests
now routinely in use [17]. In 2012, the National TB
control programme of Bangladesh (NTP) adopted rapid
tests such as automated real time PCR (Xpert MTB/
RIF) and Line probe assays to diagnose MDR-TB/Ri-
fampicin resistant TB (RR-TB) as recommended by the
World Health Organization [18, 19]; these methods re-
duce the time needed for diagnosis.
In Bangladesh, TB service is integrated in the basic
health care services and available in all hospitals at
sub-district level and below, in chest disease clinics,
in district and medical college hospitals and in urban
health centres run by government and non-government
organizations (NGOs) [20]. Bangladesh has a dynamic
NGO sector providing TB control services in collabor-
ation with NTP through a partnership approach [21].
Different types of health care providers administer TB
services in Bangladesh, including both qualified pri-
vate practitioners and informal providers [22, 23]. Private
practitioners are popular in Bangladesh irrespective of pa-
tients’ income level and residence [24]. However, NTP
does not have strong linkage with the private sector. As in
many other countries, TB services provided by the private
sector are poor, with use of inappropriate treatment and
poor case holding, leading to incomplete treatment and
drug resistance [24].
Delays in the treatment of drug-sensitive TB patients
have been reported in several studies carried out in
Bangladesh [3, 25–27]. Our study aims to explore de-
lays related to the commencement of treatment for
MDR-TB patients caused by the health system, namely
provider delay, diagnostic delay and treatment initiation
delay. Further, we aim to explore possible factors re-
lated to the health system delay, as well as to offer po-
tential solutions.
Methods
Study population and setting
MDR-TB patients were identified as part of a previ-
ously conducted case–control study on risk factors
associated with MDR-TB in Bangladesh when infor-
mation related to treatment delay was also collected
[28]. The study included 250 MDR-TB and 750 non-
MDR-TB tuberculosis patients. In the current study
we restrict the analysis to data related to the delay in
treatment of MDR-TB patients.
NTP Bangladesh adopted the standardized regimen
for treating MDR-TB and started the DOTS Plus project,
in 2008 [29]. Currently one hospital at national level and
four at regional level are providing MDR-TB diagnosis
and treatment services. These hospitals are equipped
with reference laboratories and a MDR-TB treatment
ward. Presumptive MDR-TB patients who are identified
at the district, sub-district or lower level are referred to
these central and regional level hospitals for diagnosis
and treatment initiation of MDR-TB, according to the
national guideline [29].
At the time of our data collection, MDR-TB patients
from all over Bangladesh (central, district and subdis-
trict level) were referred to one of three government
hospitals, i.e. the national hospital in Dhaka or a re-
gional hospital in either Chittagong or Rajshahi. All eli-
gible MDR-TB patients from these hospitals who were
admitted from September 2012 to mid-April 2013 were
recruited. At that time the rapid diagnostic tests were
still evolving in Bangladesh, and some of the MDR-TB
patients were diagnosed through the conventional
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culture and DST method. We only included the MDR-
TB patients diagnosed by rapid diagnosis tests to en-
sure valid comparisons.
Except for the diagnostic criteria, the inclusion and
exclusion criteria of this study were similar to the pre-
vious study [28]. The NTP has adopted automated real
time PCR (Xpert MTB/RIF) as the preferred rapid diag-
nostic tool of MDR-TB patients. Culture and Drug Sen-
sitivity Testing (DST) and Line probe assays were also
used by NTP [29]. Xpert MTB/RIF diagnoses only Ri-
fampicin resistance. However, patients who are resistant
to Rifampicin are generally also resistant to Isoniazid
(another first-line drug). Mono-resistance to Rifampicin
is fairly uncommon (0.2 % and 0.4 % among new and
previously treated patients, respectively), as shown by a
recent drug resistance survey (DRS) conducted in
Bangladesh [30]. This study included 207 MDR-TB
patients who were diagnosed by the rapid tests, i.e.
Xpert MTB/RIF or Line probe assays, to maintain the
consistency in overall delay related information. We
had excluded 34 patients who were diagnosed by the
conventional culture and DST method. Nine patients
were excluded due to missing information. The NTP
uses a laboratory based in Antwerp, Belgium as quality
control for diagnosis of MDR-TB patients.
Data collection and definitions
Definitions used in this study are as follows: Provider
delay: time between visiting a provider to visiting desig-
nated diagnostic centre for testing; Diagnostic delay:
time between the diagnostic sample provided to date
the result is available; Treatment initiation delay: time
between the date of diagnosis and the date of treatment
initiation; Health system delay: time between visiting a
provider to start of treatment. Health system delay was
derived by adding provider delay, diagnostic delay and
treatment initiation delay (Fig. 1). In this study, the
term private practitioner refers to clinicians who are at
least medical graduates; informal providers are the one
without medical degree (MBBS), i.e. village doctors,
medical assistants.
We tried to keep the definitions in line with a study
conducted in Bangladesh that focused on treatment
delay among drug sensitive TB patients due to health
care providers [3]. Delay-related definitions used for
drug-sensitive TB were not completely applicable to
MDR-TB. As it is difficult to estimate patient delay
(defined as the time between the onset of symptom
to visiting a health care provider) for MDR-TB, as
most of the patients had been treated previously, we
focused our study on the delay due to the health sys-
tem. We interviewed patients regarding their first visit
to a health provider, assuming the patient would visit
a provider when they perceived the symptoms as worsen-
ing or suspected a lack of response to their ongoing treat-
ment. The provider delay in our study is based on
patients’ perceptions. Most of the participants (97 %) were
TB patients who had previously received treatment for
TB. We asked the patients specifically how many weeks
before the MDR-TB diagnosis they had visited a health
provider for their current problem (i.e. worsening of TB
symptoms, or feeling that the disease was not responding
to treatment).
Trained investigators collected information from the
study participants by face-to-face interview using a
pre-tested questionnaire, and by review of records. In-
formation related to the time frame of the patient’s
visit to the provider was collected through interview,
and since their recall may not be accurate, it was
expressed in weeks rather than days. The dates of
diagnosis and treatment were taken from the hospital
records, and the diagnostic and treatment delays were
expressed in days.
Statistical analysis
Socio-demographic characteristics were summarised
using means and standard deviations for continuous
variables and counts/percentages for categorical vari-
ables. Multivariable regression models were used to
estimate the effect of age, sex, education, occupation,
residence status, type of TB the patient, and the pro-
vider visited for first consultation, on health system


















Fig. 1 Definition of delays used in this study. Adapted from: Rifat M, Rusen ID, Islam MA, Enarson DA, Ahmed F, Ahmed SM, Karim F: Why are
tuberculosis patients not treated earlier? A study of informal health practitioners in Bangladesh. International Journal of Tuberculosis & Lung Disease
2011, 15(5):647–651
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as education, occupation, residence status and income in
the multivariable analysis, assuming that these characteris-
tics may influence the choice of provider and affect the
health system delay. Since the distribution of delay was
skewed, we used Bootstrap variance estimators for regres-
sion analysis. Regression coefficients are presented with
95 % confidence intervals and associated p values for sim-
ple and Omnibus hypotheses. Data analysis was carried
out using Stata statistical software version 12 (StataCorp
LP, TX, USA).
Limitation of the study
This study includes only patients who were already en-
rolled in MDR-TB treatment. We do not have informa-
tion about patients who did not start treatment after
diagnosis. Unlike with the delay in drug-sensitive TB
patients, it is difficult to determine the date for the on-
set of symptoms that prompted a visit to a clinician
among the MDR-TB patients. Information related to
provider delay was based on patients’ information
recalled during face-to-face interviews, and could not
be verified.
Ethics considerations
The study was approved by the Human Research Ethics
Committee (HREC) of the University of Newcastle
(UoN), Australia, and the Bangladesh Medical Research
Council (BMRC), Dhaka, Bangladesh. An information
sheet describing the purpose of the study and the in-
dividuals’ rights as study participants was handed to
each participant to read. For individuals with inad-
equate literacy, the information sheet was read out by
the interviewers. Participants consented by signing the
consent form, or if unable to do so, by adding their
thumb impression. All patients had been treated through
NTP Bangladesh.
Results
Socio-demographic characteristics of the patients are
presented in Table 1. The median delay caused by
health system factors was 7.1 weeks. Provider delay
(median 4 weeks), diagnostic delay (median 5 days)
and treatment initiation delay (median 10 days) make
up the health system delay (Table 2).
Total 89 MDR-TB patients (43.8 %) consulted a pri-
vate practitioner first, for their MDR-TB related symp-
tom (Table 1), which included 86 previously treated TB
patients. Only 9.5 % of the previously treated TB pa-
tients had been treated in the private sector for their
previous TB disease and the rest (90.5 %) were treated
in a DOTS centre (not shown in table).
Multivariable regression analysis (Table 3) of health
system and associated factors causing delay in the treat-
ment of MDR-TB patients are shown in Table 3. Patients
Table 1 Socio-demographic and clinical characteristics of the
multidrug resistant tuberculosis (MDR-TB) patients in Bangladesh







Secondary and below 169 (70.1)
Higher secondary and above 19 (7.9)













Factory worker 16 (7.7)
Business 36 (17.4)
Self employed 12 (5.8)
Transport worker 9 (4.4)
Smoking status
Smoker 103 (49.8)
Non- smoker 104 (50.2)
Type of TB patient
New 5 (2.4)
Previously treated 202 (97.6)
Treatment outcome of previously treated patients
Cured 16 (7.9)
Completed 37 (18.3)
Default from treatment 5 (2.5)
Treatment failure 119 (58.9)
No record available 25 (12.4)
Age (mean ± SD) 34 ± 12.0
Income (mean ± SD) 13664.3 ± 11521.7
Age and Income are expressed in the table is the mean ± Standard Deviation.
All other variables are expressed as n (%)
Income is in Bangladeshi taka (BDT), monthly. 1 USD =78 BDT approximately
DOTS: National TB control programme designated centres for TB treatment
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who visiting private practitioners for the first consult-
ation experienced a greater health system delay com-
pared to those visiting the NTP designated DOTS centre
(mean difference, 37.7 days; 95 % CI 15.0–60.4; p 0.003).
Discussion
Our study found that time taken for diagnosis of MDR-
TB is five days since the introduction of rapid tests in
the programme; subsequently it took ten days to initiate
treatment. A recent study on pre-diagnosis and pre-
treatment attrition of MDR-TB patients of Bangladesh
presented the median time for diagnosis and treatment
initiation as four and five days, respectively [31]. The
study included 163 MDR-TB patients diagnosed by
Xpert MTB/RIF from selective areas which are sup-
ported by one NGO (BRAC) in Bangladesh. Whereas,
our study included patients from all three government
hospitals providing MDR-TB services at that time,
which included patients referred from all areas of
Bangladesh (including the area not supported by BRAC),
during the study period. Laboratory turnaround time re-
ported by another study conducted in Cape Town, South
Africa was less than one day using Xpert based algorithm
and 24 days using Line probe assay based algorithm [10].
The study also reported time to initiate treatment after
diagnosis as 10 and 14 days in Xpert and Line probe assay
based algorithm, respectively [10]. Similar results were
found in a multicounty study which reported median time
to detect rifampicin resistant as one day for Xpert MTB/
RIF test and 20 days for Line Probe Assay based test [8].
Another study on MTB-DR Plus showed reduction in la-
boratory processing time (median 22 days) compared to
culture based DST which was 55 days; whereas it took
20 days of operational delay to start the treatment [14].
Diagnosis time using MTB-DR plus was also reported
as 4.2 and 11 days in Georgia and India, respectively
[15, 32]. In our study, time needed for diagnosis is sat-
isfactory. However, there was a remarkable delay in
treatment initiation before the diagnosis, which was
also observed in other studies on rapid tests for MDR-
TB diagnosis [10, 14].
Unlike most other studies on the delay to treatment of
MDR-TB patients, the definition of health system delay
in our study includes the delay related to the visit to the
health care provider. Median health system delay is
7.1 weeks in our study, which is mainly due to provider
delay (4 weeks). Those patients who visited a private
practitioner after perceiving their symptom during their
current MDR-TB episode, experienced longer health sys-
tem delays than patients who visited a NTP designated
DOTS centre. In another study on drug sensitive TB
patients in Bangladesh, visiting informal providers was
associated with longer health system delay [3]. In con-
trast, we did not find any association between delay in
treatment and visiting informal providers. MDR-TB pa-
tients may prefer qualified practitioners to informal pro-
viders as treatment is more complicated. We also found
that many of the MDR-TB patients, who consulted pri-
vate practitioners first for their current problem, had
been treated in DOTS centre during previous TB treat-
ment and this group of patients were reliant on private
practitioners for their current complicated problem. This
finding indicates that the MDR-TB patients might have
visited multiple providers during the course of previous
and current TB disease. However our finding concludes
those who had in touch with private practitioners had
experienced greater health system delay.
The provider delay may be due to lack of awareness
of referral services by private practitioners. A sputum
result of drug-sensitive TB patients at 5th month or 8th
month of treatment forms the basis for a decision on
referral for MDR-TB diagnosis, according to the na-
tional guideline. Waiting for the scheduled sputum
conversion result could be another factor for provider
delay. However, the national guideline also allows clini-
cians to refer a patient for MDR-TB screening [29].
NTP and its NGO partners in Bangladesh are involved
in linking the private practitioners to the national TB
control programme [24], encouraging private practi-
tioners to refer TB patients to NTP designated DOTS
centres where they receive tuberculosis treatment free
of charge. However, many of the private practitioners
who are not linked to the NTP often do not treat the
TB patients according to the International Standards
for Tuberculosis Care (ISTC) [24, 33, 34]. Strengthen-
ing the involvement of private practitioners in TB con-
trol with emphasis on MDR-TB is needed.
Delay in treatment initiation of MDR-TB, was also re-
ported in a few other studies based on conventional
DST methods. Two studies using conventional culture
and DST for MDR-TB diagnosis reported a total time
from diagnosis to treatment initiation of 12.4 weeks and
17 weeks in Kwazulu Natal, South Africa and Cameroon,
Table 2 Delays in treatment among the multidrug resistant
tuberculosis (MDR-TB) patients of Bangladesh (n = 207)
Median IQR Mean SD
Health System delay (weeks) 7.1 8.6 (4.6–13.3) 10.5 11.25
Provider delay (weeks) 4 6 (2–8) 6.8 9.6
Diagnostic delay (days) 5 6 (1–7) 5.9 8.1
Treatment initiation delay (days) 10 17 (6–23) 20.5 28.9
Health system delay includes the provider delay, diagnostic delay and
treatment initiation delay
Diagnostic delay includes the patients who had the rapid tests such as Gene
Xpert and or LPA
Diagnostic delay, provider delay and health system delay had 3, 4 and 7
missing values, respectively
Standard deviation (SD), Interquartile range (IQR)
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respectively [11, 13]. Time for diagnosis and treat-
ment initiation using conventional culture was 246 to
283 days, respectively among children, if the informa-
tion of their MDR-TB contact was not one of the cri-
teria for diagnosis [12]. Time taken at different stages
of MDR-TB management using conventional culture
and DST method, starting from sample collection to
start of treatment, was also reported in another study
which presents a total turnaround time of 5 months
which was almost double of the bacteriological pro-
cedure [35]. To get a patient started on treatment
after diagnosis took 12.8 days in Vietnam [9].
Table 3 Factors related to health system delay of multidrug resistant tuberculosis (MDR-TB) patients of Bangladesh
Univariate analysis (n = 200) Multivariable analysis (n = 200)
Variable Median Health
system delay
Coefficienta p* 95 % Confidence
Interval
Coefficienta p* p** 95 % Confidence
Interval
Lower Upper Lower Upper
Gender
Male 51.5 Reference Reference
Female 45 −21.9 0.01 −38.9 −4.9 −18.1 0.27 −50.4 14.2
Education 0.35
No education 43 Reference Reference
Up to secondary level 50.5 4.1 0.70 −16.9 25.0 3.5 0.76 −18.7 25.7
Higher secondary and above 54.5 58.0 0.13 −17.6 133.5 58.1 0.15 −20.3 136.5
Provider visited 0.003
DOTS centrec 45 Reference Reference
Private practitioners 53 33.6 0.01 10.2 57.0 37.7 0.001 15.0 60.4
Informal provider 59.5 23.4 0.12 −5.9 52.7 26.2 0.13 −8.0 60.5
Residence status
Rural 51 Reference Reference
Urban 46 −1.3 0.89 −19.0 16.4 4.6 0.70 −19.1 28.2
Type of the patients 0.07
New TB patient 57 Reference Reference
Cured, previously treated 45 −4.2 0.83 −41.4 33.0 21.8 0.40 −29.3 72.9
Completed, previously treated 40.5 2.0 0.90 −30.1 34.0 16.5 0.54 −36.5 69.4
Default, previously treated 51 2.0 0.91 −31.1 35.1 42.6 0.16 −16.7 101.9
Failure, previously treated 54 27.4 0.14 −9.3 64.1 51.7 0.08 −5.3 108.7
No outcome recorded, previously treated 56.5 5.1 0.79 −31.3 41.4 23.9 0.42 −34.0 81.7
Occupation 0.66
None 41.5 Reference Reference
Service 51 34.7 0.02 5.4 64.0 17.1 0.34 −17.9 52.1
Farmer 54 25.0 0.10 −4.8 54.8 32.8 0.16 −12.8 78.4
Student 27 −15.3 0.14 −35.6 5.0 −21.7 0.56 −93.9 50.6
Homemaker 49 14.4 0.25 −9.9 38.7 26.2 0.12 −6.8 59.1
Factory worker 54 41.6 0.15 −15.0 98.2 36.6 0.32 −35.1 108.2
Business 48.5 31.8 0.03 2.7 60.8 8.8 0.72 −38.6 56.2
Self employed 70.5 43.9 0.07 −3.5 91.3 45.9 0.13 −13.7 105.4
Transport worker 45.5 51.0 0.24 −33.8 135.8 45.1 0.31 −41.7 131.8
Age (years) - −0.02 0.95 −0.5 0.5 −0.3 0.36 −1.0 0.4
Income (BDT)b - 0.001 0.21 −0.001 0.003 0.0003 0.71 −0.001 0.002
aRegression coefficients reflect adjusted difference in mean delay (days), while all other factors remain constant
bIncome is in Bangladeshi taka (BDT), monthly. 1 USD =78 BDT approximately
cDOTS centres are the NTP designated treatment centres for tuberculosis
p*is the value that the regression coefficient is zero
p**is the value form the omnibus test that all coefficients for that variable are zero
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Unnecessary delays should be prevented to control
further transmission of MDR-TB. The delay between
diagnosis and initiating treatment might be due to the
need for other necessary medical examinations such as
clinical tests prior to initiation of treatment (e.g. liver
function test, Xray, thyroid profile, blood sugar) [10].
Other operational issues adding to the delay might be
sample transportation, laboratory-based diagnostic and
patient notification, and admission to hospital, or may
be due to the protocol for processing smear-negative
samples [14, 35].
The reason for the delay in treatment initiation in
Bangladesh could be due to the initial hospitalization re-
quirement for MDR-TB treatment, according to the
protocol that was usually 6 to 8 months. MDR-TB pa-
tients may require preparation time to get admitted to
hospital for months. Again, those hospitals also had bed
limitation to enrol all patients at a time and patient has
to wait in queue. Need for shortening of hospital stay
was felt by the programme to make a balance between
the number of patients diagnosed by rapid tests and the
number of beds available at MDR-TB hospitals.
A pilot project on shortening hospital stay is under
way, i.e. to start ambulatory treatment after two con-
secutive negative sputum culture results. Patients were
treated as ambulatory at community level after initial
hospitalization. Ambulatory or community-based treat-
ment for MDR-TB is also recommended by the WHO,
whenever possible [2]. One study reported that the rea-
son for treatment initiation delay was due to the need
for a decision made by the Programmatic Management
of Drug Resistant TB (PMDT) Council, and the time
taken to assign the patient to the treatment support
during the long preparation phase [9]. Another study
reported that having a town address was associated
with less delay among MDR-TB and we did not find
any relationship with urban–rural status and time to
treatment, in our study [14].
Conclusion
Introduction of rapid diagnostic methods have satisfac-
tory time needed for MDR-TB diagnosis. Treatment ini-
tiation subsequent to diagnosis was delayed may be due
to programmatic factors. This could be improved by
identifying specific problems of implementation at
programme level. Engaging private practitioners in na-
tional MDR-TB control programme should be enhanced
to reduce the overall delay in MDR-TB management.
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